Real-World Mobocertinib Data Lay Groundwork for Further EGFR+ NSCLC Research
Leora Horn, MD, discusses how real-world data of mobocertinib as treatment of refractory EGFR-positive non–small cell lung cancer and other real-world studies can impact the treatment paradigm.
Leora Horn, MD, associate professor of cancer research, Vanderbilt Ingram Cancer Center, associate professor of medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, discusses how real-world data of mobocertinib as treatment of refractory EGFR-positive non–small cell lung cancer and other real-world studies can impact the treatment paradigm.
Recent data observed in patients with EGFR-positive non–small cell lung cancer (NSCLC) shows the power of real-world data in the field, explains Horn. Although the data are not perfect because database information can vary, information from real-world studies has the potential to set the bar for clinical trial research.
According to Horn, real-world data does sometimes reinforce what has been previously observed with targeted therapies in the clinical trial setting. This gives oncologists gratification that patients are receiving good care.
Horn also explains that clinical trials are still important and oncologists across the county should work in collaboration to get patients with EGFR-positive NSCLC and other forms of lung cancer enrolled in clinical trials.
FDA Grants Breakthrough Therapy Designation to Sunvozertinib in EGFR Exon20+ NSCLC
April 9th 2024Sunvozertinib was granted breakthrough therapy designation by the FDA for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer harboring an EGFR exon 20 insertion mutation.
Read More
Amivantamab/Lazertinib Still Effective in EGFRm NSCLC Despite Dose Interruptions
March 26th 2024According to a subset analysis of the phase 3 MARIPOSA trial, dose interruptions during the course of amivantamab and lazertinib treatment were still effective in EGFR-mutant non-small cell lung cancer.
Read More
